Lab
Bioreference Health, LLC
Bioreference Health, LLC was paid $8K by Medicaid between Nov 2018 and Oct 2024, across 28 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 51% of everything it billed.
33Billing provider infoBIOREFERENCE HEALTH, LLC
GAITHERSBURG, MD 20877
GAITHERSBURG, MD 20877
33aNPI1528331881assigned 02/17/2012
33bProvider typeClinical Medical Laboratory
28Total paid$8K
24GClaims4,591
24DCodes billed28
24AFirst – last monthNov 2018 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Maryland
Rank by total paid#73 of 93
Median peer was paid$430K
This provider vs. median0.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17 | $0.00 | |
| 2019 | 16 | $0.00 | |
| 2020 | 874 | $5K | |
| 2021 | 1,353 | $2K | |
| 2022 | 816 | $260.00 | |
| 2023 | 818 | $494.92 | |
| 2024incomplete | 697 | $148.55 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 51% | 309 | 302 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 16% | 25 | 25 | $1K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 8.2% | 1,129 | 1,115 | $675.31 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.5% | 762 | 750 | $368.90 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.4% | 780 | 753 | $365.81 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.8% | 214 | 211 | $318.80 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.9% | 109 | 107 | $238.75 |
| 87536 | 2.2% | 67 | 66 | $183.79 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.0% | 39 | 39 | $162.33 |
| 85610 | 1.3% | 29 | 29 | $108.64 | |
| 87481 | <1% | 81 | 75 | $79.54 | |
| 87340 | <1% | 145 | 144 | $46.64 |
16 more codes
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 32 | $38.21 |
| 86706 | <1% | 137 | $36.86 | |
| 80053 | Comprehensive metabolic panel | <1% | 62 | $33.38 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 31 | $27.30 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $26.39 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31 | $12.00 |
| 86140 | <1% | 77 | $9.00 | |
| 83010 | 0% | 40 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 36 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 135 | $0.00 |
| 86704 | 0% | 80 | $0.00 | |
| 84460 | 0% | 40 | $0.00 | |
| 86708 | 0% | 68 | $0.00 | |
| 82247 | 0% | 40 | $0.00 | |
| 82977 | 0% | 40 | $0.00 | |
| 82172 | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHMID, MICHAEL (SVP, CHIEF FINANCIAL OFFICER)
Parent organizationBIOREFERENCE HEALTH, LLC
| Provider | Location | Paid |
|---|---|---|
| Bioreference Health, LLC | Elmwood Park, NJ | $620.07M |
| Bioreference Health, LLC | Houston, TX | $8.87M |
| Florida Clinical Laboratory, INC | Melbourne, FL | $549K |
| Bioreference Health, LLC | Mineola, NY | $175K |
| Bioreference Health, LLC | Houston, TX | $117K |
| Bioreference Health, LLC | Burbank, CA | $25K |
| Bioreference Health, LLC | Hackensack, NJ | $22.86 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.